UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 5, 2019

 

MARIMED INC.

(Exact name of registrant as specified in its charter)

 

Delaware   0-54433   27-4672745
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

10 Oceana Way, Norwood, Massachusetts   02062
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (617) 795-5140

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Title of each class   Ticker symbol(s)   Name of each exchange on which registered
Not Applicable.   Not Applicable.   Not Applicable.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

     
     

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On June 5, 2019, the Registrant received a letter from Thomas Kidrin resigning from the Registrant’s board of directors, effective immediately. The letter, a copy of which is filed as Exhibit 99.1 to this Current Report, states that Mr. Kidrin’s resignation was “due to a dispute over outstanding matters.” No further explanation was provided.

 

As previously reported in its Forms 10-K and 10-Q, the Registrant contends that an employment agreement with Mr. Kidrin is not valid. The Registrant is currently evaluating commencement of legal action against Mr. Kidrin.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

  Exhibit   Description
       
  99.1   Resignation letter from Thomas Kidrin dated June 5, 2019

 

     
     

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MARIMED INC.
     
Dated: June 11, 2019    
  By:   /s/ ROBERT FIREMAN
    Robert Fireman, CEO

 

     
     

 

EXHIBIT INDEX

 

  Exhibit   Description
       
  99.1   Resignation letter from Thomas Kidrin dated June 5, 2019

 

     
     

 

MariMed (QX) (USOTC:MRMD)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more MariMed (QX) Charts.
MariMed (QX) (USOTC:MRMD)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more MariMed (QX) Charts.